The Pill is the New Shot: How Sam Chun Dang is Pioneering Oral Weight Loss & Beyond
The race to deliver weight-loss medications in pill form is heating up, and South Korea’s Sam Chun Dang Pharm (SCD) is rapidly emerging as a frontrunner. A recent surge in the company’s stock – up over 75% this month – has not only minted a new billionaire, Chairman Yoon Dae-in, but also signals a potential paradigm shift in how we approach obesity and other chronic conditions.
From Injectables to Orals: The S-Pass Revolution
For years, GLP-1 receptor agonists like Wegovy and Ozempic have dominated the weight-loss market, but their delivery method – injections – presents a barrier for many. SCD’s key innovation, S-Pass technology, aims to overcome this hurdle. S-Pass transforms injectable drugs into easily digestible pills, maintaining efficacy while dramatically improving patient convenience. This isn’t just about weight loss; the potential applications extend to diabetes, autoimmune diseases, and other conditions currently reliant on inconvenient injections.
The recent partnership with Japanese pharmaceutical giant Daiichi Sankyo to co-develop and commercialize SCD’s weight-loss pill in Japan is a testament to S-Pass’s promise. While financial details remain undisclosed, the market reacted strongly, pushing SCD shares up nearly 40% post-announcement. Korea Investment & Securities recently highlighted S-Pass’s “potential for clinical success” in oral obesity and diabetes treatments, further fueling investor confidence.
Beyond Weight Loss: A Diversified Pipeline
SCD isn’t solely focused on weight loss. The company boasts a diverse portfolio, including active pharmaceutical ingredients for dry-eye disease and high blood pressure. Their microsphere-based long-acting injectable technology is another key area of innovation. This system utilizes timed-release micro-pellets to deliver medication slowly over months, reducing the frequency of injections.
A significant deal struck in January 2025 with Takeda, worth up to $2 billion, showcases this technology. SCD will develop and sell a long-acting injectable version of leuprorelin, a prostate cancer medication, in the U.S. The agreement includes $100 million upfront and milestone payments, plus a 50-50 profit share on the remaining $1.9 billion. This demonstrates SCD’s ability to not only innovate but also secure lucrative partnerships with established pharmaceutical leaders.
The Rise of Korean Biotech: A Growing Trend
SCD’s success is part of a larger trend: the burgeoning Korean biotech industry. The country is rapidly becoming a global hub for pharmaceutical innovation, with several companies now boasting billionaire founders. Yoon Dae-in joins the ranks of Seo Jung-jin (Celltrion), Park Soon-jae (Alteogen), Chung Yong-ji (Caregen), Lee Sang-hoon (ABL Bio), Jung Sang-soo (PharmaResearch), and Hyuntae Kim (Voronoi) – all pioneers driving advancements in areas like biosimilars, anti-wrinkle treatments, and AI-powered drug discovery.
Did you know? South Korea’s government has actively invested in the biotech sector, providing funding and incentives to encourage research and development.
Financial Performance & Historical Context
SCD’s financial performance reflects its growing momentum. Revenue increased by 6.3% year-over-year to 165.5 billion won ($113 million) in the first nine months of 2025, with net income soaring 76% to 70 billion won.
Founded in 1943 during the Japanese occupation as Chosun Sam Chun Dang, the company underwent a transformation in 1986 when Yoon Dae-in, leveraging family funds, acquired it after completing his MBA. SCD went public on the Kosdaq exchange in 2000, raising 9.1 billion won in its IPO.
What Does the Future Hold?
The success of SCD and its peers suggests several key trends will shape the pharmaceutical landscape in the coming years:
- Oral Drug Delivery: Expect increased investment in technologies like S-Pass to convert injectables into pills, improving patient adherence and market access.
- Long-Acting Injectables: Microsphere technology and similar systems will become more prevalent, offering convenience and sustained drug release.
- Strategic Partnerships: Collaboration between innovative biotech firms and established pharmaceutical companies will be crucial for navigating regulatory hurdles and scaling up production.
- The Korean Biotech Boom: South Korea will continue to attract investment and talent, solidifying its position as a global biotech powerhouse.
Pro Tip: Keep an eye on clinical trial data for SCD’s weight-loss pill. Positive results will likely drive further stock appreciation and attract even more attention from potential partners.
FAQ
Q: What is S-Pass technology?
A: S-Pass is a drug delivery system developed by Sam Chun Dang Pharm that allows injectable medications to be formulated into oral pills.
Q: What conditions could benefit from S-Pass?
A: Initially focused on weight loss and diabetes, S-Pass has potential applications for various conditions currently treated with injections, including autoimmune diseases.
Q: Is SCD a good investment?
A: SCD’s stock has seen significant growth, but investment decisions should be based on thorough research and consideration of individual risk tolerance.
Q: What other Korean biotech companies are worth watching?
A: Celltrion, Alteogen, Caregen, ABL Bio, PharmaResearch, and Voronoi are all leading Korean biotech firms with promising pipelines.
What are your thoughts on the future of oral weight loss medications? Share your opinions in the comments below!
Explore more biotech news and analysis.
Subscribe to our newsletter for the latest updates.
